Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 19-Nov-21 10:19 AM View:  | Milinazzo Alan Director | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 27,450 | $8.50 | $233,325.00 | (100%) 27.45K to 0 | (7%) |
| 19-Nov-21 10:10 AM View: | Canute Scott A Director | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 9,000 | $8.50 | $76,500.00 | (100%) 9.0K to 0 | (7%) |
| 19-Nov-21 10:08 AM View: | Levine Mark S. General Counsel | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 133,486 | $8.50 | $1,134,630.00 | (100%) 133.49K to 0 | (7%) |
| 19-Nov-21 9:56 AM View: | Clayman Michael D. President and CEO Director | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 787,052 | $8.50 | $6,689,940.00 | (100%) 787.05K to 0 | (7%) |
| 19-Nov-21 10:14 AM View: | Kwo Elizabeth Director | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 4,500 | $8.50 | $38,250.00 | (100%) 4.5K to 0 | (7%) |
| 19-Nov-21 10:06 AM View: | Muzikant Adam Chief Business Officer | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 103,666 | $8.50 | $881,161.00 | (100%) 103.67K to 0 | (7%) |
| 19-Nov-21 10:04 AM View: | Wentworth Kerry Chief Regulatory Officer | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 140,843 | $8.50 | $1,197,170.00 | (96%) 146.84K to 6.0K | (7%) |
| 23-Nov-21 7:00 PM View: | Newtyn Management, LLC 10% Owner | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition (change in control) | 5,900,000 | -- | -- | (100%) 5.9M to 0 | |
| 19-Nov-21 10:01 AM View: | Willwerth Christina Chief Strategy Officer | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 141,241 | $8.50 | $1,200,550.00 | (100%) 141.24K to 0 | (7%) |
| 19-Nov-21 10:04 AM View: | Wentworth Kerry Chief Regulatory Officer | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 6,000 | $8.50 | $51,000.00 | (100%) 6.0K to 0 | (7%) |
| 19-Nov-21 10:12 AM View: | Colella Samuel D Director | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 9,000 | $8.50 | $76,500.00 | (< 1%) 1.5M to 1.49M | (7%) |
| 19-Nov-21 10:17 AM View: | Merrifield C Ann Director | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 19,000 | $8.50 | $161,500.00 | (100%) 19.0K to 0 | (7%) |
| 19-Nov-21 10:16 AM View: | Lukatch Heath Director | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 9,000 | $8.50 | $76,500.00 | (100%) 9.0K to 0 | (7%) |
| 19-Nov-21 10:09 AM View: | Mahaffy Patrick J Director | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 39,824 | $8.50 | $338,504.00 | (100%) 39.82K to 0 | (7%) |
| 19-Nov-21 10:20 AM View: | Stejbach Mark Director | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 12,631 | $8.50 | $107,364.00 | (100%) 12.63K to 0 | (7%) |
| 19-Nov-21 10:03 AM View: | Layman Melissa Chief Commercial Officer | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 103,956 | $8.50 | $883,626.00 | (100%) 103.96K to 0 | (7%) |
| 19-Nov-21 9:56 AM View: | Clayman Michael D. President and CEO Director | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 335,498 | $8.50 | $2,851,730.00 | (30%) 1.12M to 787.05K | (7%) |
| 19-Nov-21 10:00 AM View: | Driscoll Frederick W Chief Financial Officer | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 30,680 | $8.50 | $260,780.00 | (100%) 30.68K to 0 | (7%) |
| 19-Nov-21 10:12 AM View: | Colella Samuel D Director | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 1,487,560 | $8.50 | $12,644,300.00 | (100%) 1.49M to 0 | (7%) |
| 19-Nov-21 9:58 AM View: | Andrews William T. Chief Medical Officer | Flexion Therapeutics, Inc. (FLXN) | 19-Nov-21 | Disposition | 34,250 | $8.50 | $291,125.00 | (100%) 34.25K to 0 | (7%) |
| 20-Jul-21 8:49 PM View: | Wentworth Kerry Chief Regulatory Officer | Flexion Therapeutics, Inc. (FLXN) | 19-Jul-21 | Market Sale | 3,944 | $6.45 | $25,438.80 | (3%) 150.31K to 146.36K | (42%) |
| 20-Jul-21 8:51 PM View: | Willwerth Christina Chief Strategy Officer | Flexion Therapeutics, Inc. (FLXN) | 19-Jul-21 | Market Sale | 3,945 | $6.45 | $25,445.20 | (3%) 145.19K to 141.24K | (42%) |
| 20-Jul-21 8:44 PM View: | Clayman Michael D. President and CEO Director | Flexion Therapeutics, Inc. (FLXN) | 19-Jul-21 | Payment of Exercise | 13,859 | -- | -- | (1%) 1.14M to 1.12M | |
| 20-Jul-21 8:45 PM View: | Levine Mark S. General Counsel | Flexion Therapeutics, Inc. (FLXN) | 19-Jul-21 | Market Sale | 3,945 | $6.45 | $25,445.20 | (3%) 137.43K to 133.49K | (42%) |
| 20-Jul-21 8:48 PM View: | Muzikant Adam Chief Business Officer | Flexion Therapeutics, Inc. (FLXN) | 19-Jul-21 | Market Sale | 1,870 | $6.45 | $12,061.50 | (2%) 105.54K to 103.67K | (42%) |
| 28-Jun-21 6:32 PM View: | Colella Samuel D Director | Flexion Therapeutics, Inc. (FLXN) | 24-Jun-21 | Grant | 4,500 | -- | -- | < 1% 1.49M to 1.5M | |
| 28-Jun-21 6:40 PM View: | Merrifield C Ann Director | Flexion Therapeutics, Inc. (FLXN) | 24-Jun-21 | Grant | 4,500 | -- | -- | 31% 14.5K to 19.0K | |
| 28-Jun-21 6:25 PM View: | Lukatch Heath Director | Flexion Therapeutics, Inc. (FLXN) | 24-Jun-21 | Grant | 4,500 | -- | -- | 100% 4.5K to 9.0K | |
| 28-Jun-21 6:24 PM View: | Mahaffy Patrick J Director | Flexion Therapeutics, Inc. (FLXN) | 24-Jun-21 | Grant | 4,500 | -- | -- | 13% 35.32K to 39.82K | |
| 28-Jun-21 6:30 PM View: | Stejbach Mark Director | Flexion Therapeutics, Inc. (FLXN) | 24-Jun-21 | Grant | 4,500 | -- | -- | 55% 8.13K to 12.63K | |
| 28-Jun-21 6:16 PM View: | Milinazzo Alan Director | Flexion Therapeutics, Inc. (FLXN) | 24-Jun-21 | Grant | 4,500 | -- | -- | 20% 22.95K to 27.45K | |
| 28-Jun-21 6:38 PM View: | Canute Scott A Director | Flexion Therapeutics, Inc. (FLXN) | 24-Jun-21 | Grant | 4,500 | -- | -- | 100% 4.5K to 9.0K | |
| 28-Jun-21 6:42 PM View: | Kwo Elizabeth Director | Flexion Therapeutics, Inc. (FLXN) | 24-Jun-21 | Grant | 4,500 | -- | -- | 100% 0 to 4.5K | |
| 28-Jun-21 6:04 PM View: | Clayman Michael D. President and CEO Director | Flexion Therapeutics, Inc. (FLXN) | 21-Jun-21 | Grant | 1,700 | $7.78 | $13,226.00 | < 1% 1.13M to 1.14M | |
| 28-Jun-21 6:13 PM View: | Muzikant Adam Chief Business Officer | Flexion Therapeutics, Inc. (FLXN) | 21-Jun-21 | Grant | 2,081 | $7.78 | $16,190.20 | 2% 103.45K to 105.54K | |
| 28-Jun-21 6:09 PM View: | Wentworth Kerry Chief Regulatory Officer | Flexion Therapeutics, Inc. (FLXN) | 21-Jun-21 | Grant | 539 | $7.78 | $4,193.42 | < 1% 149.77K to 150.31K | |
| 03-Jun-21 4:20 PM View: | Driscoll Frederick W Chief Financial Officer | Flexion Therapeutics, Inc. (FLXN) | 01-Jun-21 | Grant | 28,000 | -- | -- | 1045% 2.68K to 30.68K | |
| 12-May-21 5:06 PM View: | Arkowitz David Chief Financial Officer | Flexion Therapeutics, Inc. (FLXN) | 10-May-21 | Market Sale | 2,229 | $7.23 | $16,115.70 | (< 1%) 222.95K to 220.72K | (26%) |
| 16-Mar-21 5:11 PM View: | Layman Melissa Chief Commercial Officer | Flexion Therapeutics, Inc. (FLXN) | 15-Mar-21 | Market Sale | 4,520 | $11.80 | $53,336.00 | (4%) 108.48K to 103.96K | 23% |
| 03-Mar-21 6:33 PM View: | Willwerth Christina Chief Strategy Officer | Flexion Therapeutics, Inc. (FLXN) | 01-Mar-21 | Grant | 30,000 | -- | -- | 26% 115.19K to 145.19K | |
| 03-Mar-21 6:29 PM View: | Kelley Scott Chief Medical Officer | Flexion Therapeutics, Inc. (FLXN) | 01-Mar-21 | Grant | 30,000 | -- | -- | 26% 113.55K to 143.55K | |
| 03-Mar-21 6:26 PM View: | Arkowitz David Chief Financial Officer | Flexion Therapeutics, Inc. (FLXN) | 01-Mar-21 | Grant | 71,900 | -- | -- | 48% 151.05K to 222.95K | |
| 03-Mar-21 6:22 PM View: | Layman Melissa Chief Commercial Officer | Flexion Therapeutics, Inc. (FLXN) | 01-Mar-21 | Grant | 20,100 | -- | -- | 23% 88.38K to 108.48K | |
| 03-Mar-21 6:42 PM View: | Muzikant Adam Chief Business Officer | Flexion Therapeutics, Inc. (FLXN) | 01-Mar-21 | Grant | 30,000 | -- | -- | 41% 73.45K to 103.45K | |
| 03-Mar-21 6:35 PM View: | Wentworth Kerry Chief Regulatory Officer | Flexion Therapeutics, Inc. (FLXN) | 01-Mar-21 | Grant | 30,000 | -- | -- | 25% 119.77K to 149.77K | |
| 03-Mar-21 6:31 PM View: | Levine Mark S. General Counsel | Flexion Therapeutics, Inc. (FLXN) | 01-Mar-21 | Grant | 30,000 | -- | -- | 28% 107.43K to 137.43K | |
| 03-Mar-21 6:16 PM View: | Clayman Michael D. President and CEO Director | Flexion Therapeutics, Inc. (FLXN) | 01-Mar-21 | Grant | 106,100 | -- | -- | 10% 1.03M to 1.13M | |
| 23-Mar-21 7:01 PM View: | Clayman Michael D. President and CEO Director | Flexion Therapeutics, Inc. (FLXN) | 01-Feb-21 | Gift | 21,099 | -- | -- | (2%) 1.16M to 1.13M | |
| 29-Jan-21 8:19 PM View: | Layman Melissa Chief Commercial Officer | Flexion Therapeutics, Inc. (FLXN) | 28-Jan-21 | Market Sale | 2,624 | $12.55 | $32,931.20 | (3%) 91.0K to 88.38K | 27% |
| 29-Jan-21 8:17 PM View: | Clayman Michael D. President and CEO Director | Flexion Therapeutics, Inc. (FLXN) | 28-Jan-21 | Payment of Exercise | 8,776 | $12.37 | $108,559.00 | (< 1%) 1.04M to 1.03M | 26% |
